# Genesis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genesis-therapeutics

- Industry: Biotechnology
- Headquarters: Burlingame, US
- Website: www.genesistherapeutics.ai
- Total disclosed funding: $278M
- Latest round: Series B (Aug 10, 2023)
- Investors on record: 14

## About

Based in California, US, and co-founded by Evan Feinberg (CEO) and Ben Sklaroff (CTO) in 2019, Genesis Therapeutics, Inc. operates as a biotechnology company that offers an AI (artificial intelligence) based molecule discovery platform. In August 2023, the firm raised USD 224.02 million in series B funding co-led by investor Andreessen Horowitz and an undisclosed investor, with participation from other investors Menlo Ventures, Radical Ventures, Rock Springs Capital, and T. Rowe Price Associates.

The biotech company is dedicated to advancing therapies and new medicines, protein targets, and exploring untapped chemical species, for patients grappling with severe disorders by leveraging the power of AI and molecular science. Genesis Therapeutics' hallmark product is GEMS, the Genesis Exploration of Molecular Space. GEMS represents the molecular AI platform, fusing deep learning, molecular simulations, and language models for drug discovery. This platform enables the creation of potent and selective small-molecule drugs, targeting previously challenging and undruggable diseases.

The company plans to utilize the August 2023 funding to develop its pipeline of artificial intelligence-enabled programs into clinical development.

## Funding rounds

- Series B, Aug 10, 2023, $224M — Menlo Ventures, T Rowe Price, Fidelity Investments, Andreessen Horowitz, BlackRock, Rock Springs Capital, Radical Ventures, nVentures
- Series A, Aug 18, 2022 — Alumni Ventures Group
- Series A, Nov 24, 2020, $50M — Menlo Ventures, T Rowe Price, Andreessen Horowitz, Felicis Ventures, Ulu Ventures, Open Field Capital, Rock Springs Capital, Radical Ventures, JAZZ Venture Partners, Propagator Ventures
- Seed, Jun 2, 2020 — Ulu Ventures
- Seed, Nov 21, 2019, $4.1M — Andreessen Horowitz, Felicis Ventures

## Investors

- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed, Series A, Series B
- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Seed, Series A
- Ulu Ventures (https://capitalatlas.ai/funds/ulu-ventures) — Seed, Series A
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series A, Series B
- Open Field Capital (https://capitalatlas.ai/funds/open-field-capital) — Series A
- Rock Springs Capital — Series A, Series B
- Radical Ventures (https://capitalatlas.ai/funds/radical-ventures) — Series A, Series B
- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Series A
- Propagator Ventures (https://capitalatlas.ai/funds/propagator-ventures) — Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- nVentures — Series B